Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

Rhea-AI Summary

Tevogen Bio Holdings (NASDAQ: TVGN) has announced that its executive officers and board members collectively own over 74% of the company's outstanding shares, as reported in their July 10, 2025 Form 8-K filing. CEO Dr. Ryan Saadi emphasized that this majority control ensures strategic decision-making remains with the management team.

The company confirmed it is well-funded to advance its development of off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, alongside its artificial intelligence initiative, Tevogen.AI. Additional details are expected to be released in the near future.

Positive

• High insider ownership of 74% demonstrates strong management confidence and alignment with shareholder interests
• Company reports being well-funded for next development phases
• Management maintains strategic control for rapid growth decisions
• Dual focus on T cell therapeutics and AI development shows technological diversification

Negative

• Limited operating history poses execution risks
• Additional capital may be needed to execute business plan
• Potential regulatory challenges for therapeutic developments
• High insider ownership could limit public float and stock liquidity

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.

Executive officers and members of Tevogen’s Board of Directors collectively hold over 74% of the Company’s outstanding shares. This substantial insider ownership reflects the leadership’s deep conviction in Tevogen’s mission, progress, and long-term strategy, setting the Company apart from many of its industry peers.

“By retaining majority control, decision making on direction and continued rapid growth remains in the hands of our team, which is critical to our strategic philosophy as well as our aspiration to redefine the future of medicine.” said Tevogen CEO Dr. Ryan Saadi. “The Company is also well funded for the next steps in developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers along with advancing our artificial intelligence effort, Tevogen.AI. We look forward to sharing more details in the coming days.”

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com

FAQ

What percentage of Tevogen Bio (NASDAQ:TVGN) stock is owned by insiders as of July 2025?

According to the July 10, 2025 Form 8-K filing, Tevogen's executive officers and board members collectively own over 74% of the company's outstanding shares.

What is Tevogen Bio's (TVGN) main therapeutic focus?

Tevogen Bio is developing off-the-shelf, genetically unmodified T cell therapeutics for treating infectious diseases and cancers.

How will the high insider ownership affect Tevogen's (TVGN) decision-making?

The 74% insider ownership ensures that strategic decision-making and growth direction remain controlled by the management team, as emphasized by CEO Dr. Ryan Saadi.

What is Tevogen.AI and how does it fit into the company's strategy?

Tevogen.AI is the company's artificial intelligence initiative that is being developed alongside their T cell therapeutics program, demonstrating their commitment to technological advancement.

What are the main risks facing Tevogen Bio (TVGN) according to their forward-looking statements?

Key risks include the need for additional capital, regulatory challenges, competition in rapidly evolving markets, and the company's limited operating history.